We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+47.12%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$367M
AUM Growth
-$744K
Cap. Flow
-$75M
Cap. Flow %
-20.41%
Top 10 Hldgs %
48.04%
Holding
60
New
17
Increased
14
Reduced
15
Closed
9

Top Buys

Rank Stock Value
1
BLSA
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
+$9.03M
2
REPL icon
Replimune Group
REPL
+$8.65M
3
VTGN icon
VistaGen Therapeutics
VTGN
+$6.38M
4
JYAC
Jiya Acquisition Corp. Class A Common Stock
JYAC
+$5.73M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$4.66M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$43.5M
2
KURA icon
Kura Oncology
KURA
+$11.8M
3
ALDX icon
Aldeyra Therapeutics
ALDX
+$10.2M
4
CYTK icon
Cytokinetics
CYTK
+$7.74M
5
LSACU
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
+$7.62M

Sector Composition

Rank Sector Weight
1 Healthcare 89.24%
2 Financials 4.13%
3 Industrials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLDX icon
1
Celldex Therapeutics
CLDX
$2.96B
$28.5M 7.76%
1,627,500
+82,500
+5% +$1.48M
SAGE
2
DELISTED
Sage Therapeutics
SAGE
$22.1M 6.02%
255,800
+30,800
+14% +$2.27M
KURA icon
3
Kura Oncology
KURA
$816M
$20.8M 5.67%
637,500
-335,500
-34% -$11.8M
LRMR icon
4
Larimar Therapeutics
LRMR
$413M
$18.5M 5.03%
863,100
+33,100
+4% +$663K
MRSN
5
DELISTED
Mersana Therapeutics
MRSN
$18.5M 5.03%
27,760
+1,060
+4% +$589K
CMPS
6
Compass Pathways
CMPS
$1.52B
$15.2M 4.14%
319,000
-71,000
-18% -$3.03M
VTGN icon
7
VistaGen Therapeutics
VTGN
$10.1M
$14.6M 3.96%
+250,000
New +$6.38M
LONA
8
LeonaBio Inc
LONA
$70.2M
$13.5M 3.66%
39,300
+3,050
+8% +$720K
IMVT icon
9
Immunovant
IMVT
$7.91B
$13.1M 3.56%
283,500
+33,500
+13% +$1.55M
TRIL
10
DELISTED
Trillium Therapeutics Inc.
TRIL
$11.8M 3.21%
803,000
-50,000
-6% -$721K
ARWR icon
11
Arrowhead Research
ARWR
$12.1B
$10.7M 2.9%
139,000
+37,500
+37% +$2.4M
ETNB
12
DELISTED
89bio
ETNB
$10.6M 2.88%
434,400
+16,900
+4% +$432K
SNDX icon
13
Syndax Pharmaceuticals
SNDX
$1.7B
$10.4M 2.82%
465,500
+224,756
+93% +$4.66M
APLS
14
DELISTED
Apellis Pharmaceuticals
APLS
$9.55M 2.6%
167,054
– –
BLSA
15
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$9.38M 2.55%
+842,500
New +$9.03M
SURF
16
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$9.23M 2.51%
999,500
-88,500
-8% -$769K
GYRE icon
17
Gyre Therapeutics
GYRE
$681M
$8.57M 2.33%
181,000
-18,720
-9% -$811K
ISEE
18
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.38M 2.28%
1,212,500
+410,000
+51% +$2.62M
FULC icon
19
Fulcrum Therapeutics
FULC
$283M
$7.99M 2.17%
682,500
+301,000
+79% +$3.4M
REPL icon
20
Replimune Group
REPL
$1B
$7.92M 2.15%
+207,500
New +$8.65M
IOVA icon
21
Iovance Biotherapeutics
IOVA
$1.93B
$7.65M 2.08%
164,800
-150,200
-48% -$5.96M
CNCE
22
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$6.79M 1.85%
537,500
+237,500
+79% +$2.71M
ALT icon
23
Altimmune
ALT
$583M
$6.53M 1.78%
578,500
-109,500
-16% -$1.29M
RNAM
24
DELISTED
Avidity Biosciences
RNAM
$6.28M 1.71%
246,200
+11,200
+5% +$327K
JYAC
25
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$5.79M 1.58%
+562,500
New +$5.73M
1
2 3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Acuta Capital Partners held 60 positions worth $367M, down 0.2% from $368M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Acuta Capital Partners withdrew a net $75M in Q4 2020, closing 9 positions and reducing 15 holdings. Its most notable exit was Immunomedics Inc, an estimated $43.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 74% a quarter earlier, followed by Financials and Industrials.

Against the trend, Acuta Capital Partners opened a new position in BCLS Acquisition Corp. Class A Ordinary Shares worth $9.38M.

  • Acuta Capital Partners's largest Q4 2020 buy was BCLS Acquisition Corp. Class A Ordinary Shares: 842,500 shares worth $9.38M.
  • Acuta Capital Partners added most to Syndax Pharmaceuticals in Q4 2020, an estimated $4.66M increase.
  • Acuta Capital Partners's biggest Q4 2020 reduction was Kura Oncology, cutting an estimated $11.8M.
  • Acuta Capital Partners fully exited Immunomedics Inc in Q4 2020, selling an estimated $43.5M.
  • Acuta Capital Partners's ten largest holdings make up 48% of its $367M portfolio in Q4 2020.
  • Acuta Capital Partners opened 17 new positions and closed 9 in Q4 2020.
  • Acuta Capital Partners's portfolio value fell 0.2% quarter-over-quarter to $367M.

Based on Acuta Capital Partners's 13F filing for Q4 2020, filed 16 Feb 2021.